Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma

Cancer Cell

Volumn 30, Issue 1, 2016, Pages 27-42

  Hedegaard, Jakob ^a   Lamy, Philippe ^a   Nordentoft, Iver ^a   Algaba, Ferran ^b   Høyer, Søren ^a   Ulhøi, Benedicte Parm ^a   Vang, Søren ^a   Reinert, Thomas ^a   Hermann, Gregers G ^c   Mogensen, Karin ^c   Thomsen, Mathilde Borg Houlberg ^a   Nielsen, Morten Muhlig ^a   Marquez, Mirari ^d   Segersten, Ulrika ^e   Aine, Mattias ^f   Höglund, Mattias ^f   Birkenkamp Demtröder, Karin ^a   Fristrup, Niels ^a   Borre, Michael ^a   Hartmann, Arndt ^g   Stöhr, Robert ^g   Wach, Sven ^g   Keck, Bastian ^g   Seitz, Anna Katharina ^h   Nawroth, Roman ^h   Maurer, Tobias ^h   Tulic, Cane ⁱ   Simic, Tatjana ⁱ   Junker, Kerstin ^j   Horstmann, Marcus ^k   Harving, Niels ^l   Petersen, Astrid Christine ^l   Calle, M Luz ^m   Steyerberg, Ewout W ⁿ   Beukers, Willemien ⁿ   van Kessel, Kim E M ⁿ   Jensen, Jørgen Bjerggaard ^a   Pedersen, Jakob Skou ^a   Malmström, Per Uno ^e   Malats, Núria ^d   Real, Francisco X ^d,o   Zwarthoff, Ellen C ⁿ   Ørntoft, Torben Falck ^a   Dyrskjøt, Lars ^a   more..

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c FREDERIKSBERG HOSPITAL   (Denmark)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e UPPSALA UNIVERSITY   (Sweden)

^f LUND UNIVERSITY   (Sweden)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY OF BELGRADE   (Serbia)

^j SAARLAND UNIVERSITY   (Germany)

^k FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^l AALBORG UNIVERSITY HOSPITAL   (Denmark)

^m UNIVERSITY OF VIC CENTRAL UNIVERSITY OF CATALONIA   (Spain)

ⁿ ERASMUS MEDICAL CENTER   (Netherlands)

^o UNIVERSITAT POMPEU FABRA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOBEC GENE; ARTICLE; CANCER PROGNOSIS; CELL CYCLE; CELL DIFFERENTIATION; CHROMATIN STRUCTURE; CYTOSKELETON; EARLY CANCER; EPITHELIAL MESENCHYMAL TRANSITION; ERBB2 GENE; FEMALE; GENE MUTATION; GENE PRODUCT; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; MALE; NON MUSCLE INVASIVE BLADDER CANCER; ONCOGENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; URINARY TRACT CARCINOMA; BLADDER TUMOR; CANCER STAGING; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; MUTATION; PATHOLOGY; PROCEDURES; SEQUENCE ANALYSIS; SURVIVAL ANALYSIS;

APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE; LONG UNTRANSLATED RNA; TUMOR MARKER;

APOBEC DEAMINASES; BIOMARKERS, TUMOR; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MUTATION; NEOPLASM STAGING; RNA, LONG NONCODING; SEQUENCE ANALYSIS, RNA; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84979732333     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.05.004     Document Type: Article

References (53)

1. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Borresen-Dale, A.L., et al. Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
2. Babjuk, M., Burger, M., Zigeuner, R., Shariat, S.F., van Rhijn, B.W., Comperat, E., Sylvester, R.J., Kaasinen, E., Bohle, A., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur. Urol. 64 (2013), 639–653.
3. Birkenkamp-Demtroder, K., Nordentoft, I., Christensen, E., Hoyer, S., Reinert, T., Vang, S., Borre, M., Agerbaek, M., Jensen, J.B., Orntoft, T.F., Dyrskjot, L., Genomic alterations in liquid biopsies from patients with bladder cancer. Eur. Urol., 2016, 10.1016/j.eururo.2016.01.007.
4. Biton, A., Bernard-Pierrot, I., Lou, Y., Krucker, C., Chapeaublanc, E., Rubio-Perez, C., Lopez-Bigas, N., Kamoun, A., Neuzillet, Y., Gestraud, P., et al. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes. Cell Rep. 9 (2014), 1235–1245.
5. Blaveri, E., Simko, J.P., Korkola, J.E., Brewer, J.L., Baehner, F., Mehta, K., Devries, S., Koppie, T., Pejavar, S., Carroll, P., Waldman, F.M., Bladder cancer outcome and subtype classification by gene expression. Clin. Cancer Res. 11 (2005), 4044–4055.
6. Brockdorff, N., Noncoding RNA and polycomb recruitment. RNA 19 (2013), 429–442.
7. Cancer Genome Atlas Research Network, Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507 (2014), 315–322.
8. Choi, W., Czerniak, B., Ochoa, A., Su, X., Siefker-Radtke, A., Dinney, C., McConkey, D.J., Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat. Rev. Urol. 11 (2014), 400–410.
9. Choi, W., Porten, S., Kim, S., Willis, D., Plimack, E.R., Hoffman-Censits, J., Roth, B., Cheng, T., Tran, M., Lee, I.L., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25 (2014), 152–165.
10. Cingolani, P., Platts, A., Wang le, L., Coon, M., Nguyen, T., Wang, L., Land, S.J., Lu, X., Ruden, D.M., A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6 (2012), 80–92.
11. Damrauer, J.S., Hoadley, K.A., Chism, D.D., Fan, C., Tiganelli, C.J., Wobker, S.E., Yeh, J.J., Milowsky, M.I., Iyer, G., Parker, J.S., Kim, W.Y., Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl. Acad. Sci. USA 111 (2014), 3110–3115.
12. de Bruin, E.C., McGranahan, N., Mitter, R., Salm, M., Wedge, D.C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A.J., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346 (2014), 251–256.
13. Dyrskjot, L., Thykjaer, T., Kruhoffer, M., Jensen, J.L., Marcussen, N., Hamilton-Dutoit, S., Wolf, H., Orntoft, T.F., Identifying distinct classes of bladder carcinoma using microarrays. Nat. Genet. 33 (2003), 90–96.
14. Dyrskjot, L., Kruhoffer, M., Thykjaer, T., Marcussen, N., Jensen, J.L., Moller, K., Orntoft, T.F., Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 64 (2004), 4040–4048.
15. Dyrskjot, L., Zieger, K., Real, F.X., Malats, N., Carrato, A., Hurst, C., Kotwal, S., Knowles, M., Malmstrom, P.U., de la Torre, M., et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin. Cancer Res. 13 (2007), 3545–3551.
16. Dyrskjot, L., Reinert, T., Novoradovsky, A., Zuiverloon, T.C., Beukers, W., Zwarthoff, E., Malats, N., Real, F.X., Segersten, U., Malmstrom, P.U., et al. Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR. Br. J. Cancer 107 (2012), 1392–1398.
17. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–E386.
18. Gallego Romero, I., Pai, A.A., Tung, J., Gilad, Y., RNA-seq: impact of RNA degradation on transcript quantification. BMC Biol., 12, 2014, 42.
19. Gehring, J.S., Fischer, B., Lawrence, M., Huber, W., SomaticSignatures: inferring mutational signatures from single-nucleotide variants. Bioinformatics 31 (2015), 3673–3675.
20. Gonzalez-Perez, A., Perez-Llamas, C., Deu-Pons, J., Tamborero, D., Schroeder, M.P., Jene-Sanz, A., Santos, A., Lopez-Bigas, N., IntOGen-mutations identifies cancer drivers across tumor types. Nat. Methods 10 (2013), 1081–1082.
21. Han, L., Diao, L., Yu, S., Xu, X., Li, J., Zhang, R., Yang, Y., Werner, H.M., Eterovic, A.K., Yuan, Y., et al. The genomic landscape and clinical relevance of a-to-I RNA editing in human cancers. Cancer Cell 28 (2015), 515–528.
22. Hong, Y.M., Loughlin, K.R., Economic impact of tumor markers in bladder cancer surveillance. Urology 71 (2008), 131–135.
23. Jung, S., Wu, C., Eslami, Z., Tanguay, S., Aprikian, A., Kassouf, W., Brimo, F., The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu. Ann. Diagn. Pathol. 18 (2014), 27–32.
24. Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., Salzberg, S.L., TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol., 14, 2013, R36.
25. Kim, J., Akbani, R., Creighton, C.J., Lerner, S.P., Weinstein, J.N., Getz, G., Kwiatkowski, D.J., Invasive bladder cancer: genomic insights and therapeutic promise. Clin. Cancer Res. 21 (2015), 4514–4524.
26. Lawson, D.A., Bhakta, N.R., Kessenbrock, K., Prummel, K.D., Yu, Y., Takai, K., Zhou, A., Eyob, H., Balakrishnan, S., Wang, C.Y., et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 526 (2015), 131–135.
27. Maraver, A., Fernandez-Marcos, P.J., Cash, T.P., Mendez-Pertuz, M., Duenas, M., Maietta, P., Martinelli, P., Munoz-Martin, M., Martinez-Fernandez, M., Canamero, M., et al. NOTCH pathway inactivation promotes bladder cancer progression. J. Clin. Invest. 125 (2015), 824–830.
28. McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., DePristo, M.A., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20 (2010), 1297–1303.
29. Montes, M., Nielsen, M.M., Maglieri, G., Jacobsen, A., Hojfeldt, J., Agrawal-Singh, S., Hansen, K., Helin, K., van de Werken, H.J., Pedersen, J.S., Lund, A.H., The lncRNA MIR31HG regulates p16(INK4A) expression to modulate senescence. Nat. Commun., 6, 2015, 6967.
30. Nie, F.Q., Ma, S., Xie, M., Liu, Y.W., De, W., Liu, X.H., Decreased long noncoding RNA MIR31HG is correlated with poor prognosis and contributes to cell proliferation in gastric cancer. Tumour Biol., 2015, 10.1007/s13277-015-4644-z.
31. Nordentoft, I., Lamy, P., Birkenkamp-Demtroder, K., Shumansky, K., Vang, S., Hornshoj, H., Juul, M., Villesen, P., Hedegaard, J., Roth, A., et al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep. 7 (2014), 1649–1663.
32. Patschan, O., Sjodahl, G., Chebil, G., Lovgren, K., Lauss, M., Gudjonsson, S., Kollberg, P., Eriksson, P., Aine, M., Mansson, W., et al. A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma. Eur. Urol. 68 (2015), 824–832.
33. Rampias, T., Vgenopoulou, P., Avgeris, M., Polyzos, A., Stravodimos, K., Valavanis, C., Scorilas, A., Klinakis, A., A new tumor suppressor role for the Notch pathway in bladder cancer. Nat. Med. 20 (2014), 1199–1205.
34. Rebouissou, S., Bernard-Pierrot, I., de Reynies, A., Lepage, M.L., Krucker, C., Chapeaublanc, E., Herault, A., Kamoun, A., Caillault, A., Letouze, E., et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci. Transl. Med., 6, 2014, 244ra291.
35. Roberts, S.A., Lawrence, M.S., Klimczak, L.J., Grimm, S.A., Fargo, D., Stojanov, P., Kiezun, A., Kryukov, G.V., Carter, S.L., Saksena, G., et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45 (2013), 970–976.
36. Rubio-Perez, C., Tamborero, D., Schroeder, M.P., Antolin, A.A., Deu-Pons, J., Perez-Llamas, C., Mestres, J., Gonzalez-Perez, A., Lopez-Bigas, N., In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27 (2015), 382–396.
37. Sanchez-Carbayo, M., Socci, N.D., Lozano, J., Saint, F., Cordon-Cardo, C., Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24 (2006), 778–789.
38. Shin, K., Lim, A., Zhao, C., Sahoo, D., Pan, Y., Spiekerkoetter, E., Liao, J.C., Beachy, P.A., Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer Cell 26 (2014), 521–533.
39. Sieuwerts, A.M., Willis, S., Burns, M.B., Look, M.P., Meijer-Van Gelder, M.E., Schlicker, A., Heideman, M.R., Jacobs, H., Wessels, L., Leyland-Jones, B., et al. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm. Cancer 5 (2014), 405–413.
40. Sjodahl, G., Lauss, M., Lovgren, K., Chebil, G., Gudjonsson, S., Veerla, S., Patschan, O., Aine, M., Ferno, M., Ringner, M., et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18 (2012), 3377–3386.
41. Spruck, C.H. 3rd, Ohneseit, P.F., Gonzalez-Zulueta, M., Esrig, D., Miyao, N., Tsai, Y.C., Lerner, S.P., Schmutte, C., Yang, A.S., Cote, R., et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54 (1994), 784–788.
42. Swanton, C., McGranahan, N., Starrett, G.J., Harris, R.S., Apobec enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 5 (2015), 704–712.
43. Tai, G., Ranjzad, P., Marriage, F., Rehman, S., Denley, H., Dixon, J., Mitchell, K., Day, P.J., Woolf, A.S., Cytokeratin 15 marks basal epithelia in developing ureters and is upregulated in a subset of urothelial cell carcinomas. PLoS One, 8, 2013, e81167.
44. Thorsen, K., Sorensen, K.D., Brems-Eskildsen, A.S., Modin, C., Gaustadnes, M., Hein, A.M., Kruhoffer, M., Laurberg, S., Borre, M., Wang, K., et al. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol. Cell Proteomics 7 (2008), 1214–1224.
45. Trapnell, C., Williams, B.A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M.J., Salzberg, S.L., Wold, B.J., Pachter, L., Transcript assembly and quantification by RNA-seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28 (2010), 511–515.
46. van der Horst, G., Bos, L., van der Pluijm, G., Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol. Cancer Res. 10 (2012), 995–1009.
47. van Rhijn, B.W., Vis, A.N., van der Kwast, T.H., Kirkels, W.J., Radvanyi, F., Ooms, E.C., Chopin, D.K., Boeve, E.R., Jobsis, A.C., Zwarthoff, E.C., Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J. Clin. Oncol. 21 (2003), 1912–1921.
48. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr., Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
49. Volkmer, J.P., Sahoo, D., Chin, R.K., Ho, P.L., Tang, C., Kurtova, A.V., Willingham, S.B., Pazhanisamy, S.K., Contreras-Trujillo, H., Storm, T.A., et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc. Natl. Acad. Sci. USA 109 (2012), 2078–2083.
50. Waclaw, B., Bozic, I., Pittman, M.E., Hruban, R.H., Vogelstein, B., Nowak, M.A., A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature 525 (2015), 261–264.
51. West, J.A., Davis, C.P., Sunwoo, H., Simon, M.D., Sadreyev, R.I., Wang, P.I., Tolstorukov, M.Y., Kingston, R.E., The long noncoding RNAs NEAT1 and MALAT1 bind active chromatin sites. Mol. Cell 55 (2014), 791–802.
52. Wilkerson, M.D., Hayes, D.N., ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26 (2010), 1572–1573.
53. Zhang, H., Chen, X., Wang, J., Guang, W., Han, W., Zhang, H., Tan, X., Gu, Y., EGR1 decreases the malignancy of human non-small cell lung carcinoma by regulating KRT18 expression. Sci. Rep., 4, 2014, 5416.